These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 27139040

  • 1. Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
    Al-Gousous J, Amidon GL, Langguth P.
    Mol Pharm; 2016 Jun 06; 13(6):1927-36. PubMed ID: 27139040
    [Abstract] [Full Text] [Related]

  • 2. Assessing the influence of media composition and ionic strength on drug release from commercial immediate-release and enteric-coated aspirin tablets.
    Karkossa F, Klein S.
    J Pharm Pharmacol; 2017 Oct 06; 69(10):1327-1340. PubMed ID: 28703304
    [Abstract] [Full Text] [Related]

  • 3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH, Shin S, Bulitta JB, Youn YS, Yoo SD, Shin BS.
    Mol Pharm; 2017 Jan 03; 14(1):53-65. PubMed ID: 27809538
    [Abstract] [Full Text] [Related]

  • 4. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A, Blume H, Dressman J.
    Eur J Pharm Biopharm; 2013 Nov 03; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [Abstract] [Full Text] [Related]

  • 5. The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: an in vitro/in vivo correlation.
    Stefanič M, Locatelli I, Vrečer F, Sever T, Mrhar A, Bogataj M.
    Eur J Pharm Biopharm; 2012 Oct 03; 82(2):376-82. PubMed ID: 22884655
    [Abstract] [Full Text] [Related]

  • 6. Accelerating the dissolution of enteric coatings in the upper small intestine: evolution of a novel pH 5.6 bicarbonate buffer system to assess drug release.
    Varum FJ, Merchant HA, Goyanes A, Assi P, Zboranová V, Basit AW.
    Int J Pharm; 2014 Jul 01; 468(1-2):172-7. PubMed ID: 24727141
    [Abstract] [Full Text] [Related]

  • 7. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F, Shokrollahi H.
    Int J Pharm; 2015 May 15; 485(1-2):152-9. PubMed ID: 25746736
    [Abstract] [Full Text] [Related]

  • 8. A time-scaled convolution approach to construct IVIVC for enteric-coated acetylsalicylic acid tablets.
    Al-Gousous J, Langguth P.
    Pharmazie; 2018 Feb 01; 73(2):67-69. PubMed ID: 29442006
    [Abstract] [Full Text] [Related]

  • 9. Prediction of the in vivo performance of enteric coated pellets in the fasted state under selected biorelevant dissolution conditions.
    Stefanič M, Vrečer F, Rizmal P, Mrhar A, Bogataj M.
    Eur J Pharm Sci; 2014 Oct 01; 62():8-15. PubMed ID: 24844699
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Application of the GastroDuo to study the interplay of drug release and gastric emptying in case of immediate release Aspirin formulations.
    Schick P, Sager M, Voelker M, Weitschies W, Koziolek M.
    Eur J Pharm Biopharm; 2020 Jun 01; 151():9-17. PubMed ID: 32268191
    [Abstract] [Full Text] [Related]

  • 12. Use of bicarbonate buffer systems for dissolution characterization of enteric-coated proton pump inhibitor tablets.
    Shibata H, Yoshida H, Izutsu K, Goda Y.
    J Pharm Pharmacol; 2016 Apr 01; 68(4):467-74. PubMed ID: 27019275
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Regulating the pH of bicarbonate solutions without purging gases: Application to dissolution testing of enteric coated tablets, pellets and microparticles.
    Scott N, Patel K, Sithole T, Xenofontos K, Mohylyuk V, Liu F.
    Int J Pharm; 2020 Jul 30; 585():119562. PubMed ID: 32565282
    [Abstract] [Full Text] [Related]

  • 15. Mechanistic analysis and experimental verification of bicarbonate-controlled enteric coat dissolution: Potential in vivo implications.
    Al-Gousous J, Ruan H, Blechar JA, Sun KX, Salehi N, Langguth P, Job NM, Lipka E, Loebenberg R, Bermejo M, Amidon GE, Amidon GL.
    Eur J Pharm Biopharm; 2019 Jun 30; 139():47-58. PubMed ID: 30872012
    [Abstract] [Full Text] [Related]

  • 16. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
    Varum FJ, Hatton GB, Freire AC, Basit AW.
    Eur J Pharm Biopharm; 2013 Aug 30; 84(3):573-7. PubMed ID: 23348235
    [Abstract] [Full Text] [Related]

  • 17. Predicting the gastrointestinal behaviour of modified-release products: utility of a novel dynamic dissolution test apparatus involving the use of bicarbonate buffers.
    Merchant HA, Goyanes A, Parashar N, Basit AW.
    Int J Pharm; 2014 Nov 20; 475(1-2):585-91. PubMed ID: 25195730
    [Abstract] [Full Text] [Related]

  • 18. Towards a Better Understanding of the Post-Gastric Behavior of Enteric-Coated Formulations.
    Katona MT, Kakuk M, Szabó R, Tonka-Nagy P, Takács-Novák K, Borbás E.
    Pharm Res; 2022 Jan 20; 39(1):201-211. PubMed ID: 35043354
    [Abstract] [Full Text] [Related]

  • 19. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL.
    Eur J Pharm Sci; 2015 Aug 30; 76():203-12. PubMed ID: 25978875
    [Abstract] [Full Text] [Related]

  • 20. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug.
    Okumu A, DiMaso M, Löbenberg R.
    Pharm Res; 2008 Dec 30; 25(12):2778-85. PubMed ID: 18560996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.